- Proposed acquisition strengthens Novartis immunology strategy in food allergy and other IgE-driven diseases - Lead asset Exl-111 builds on proven IgE biology with a differentiated mechanism designed to dissociate receptor-bound IgE and drive faster, deepe…
- Proposed acquisition strengthens Novartis immunology strategy in food allergy and other IgE-driven diseases- Lead asset Exl-111 builds on proven IgE biology with a differentiated mechanism designed… [+6821 chars]




